Evidence map›Paper›PMID 31328363›Full record

ArticleNeurogastroenterology and motility2019

Relationship between symptoms during a gastric emptying study and intestinal chemosensitivity with daily symptoms.

Subhankar Chakraborty, Anshuman Desai, Magnus Halland, Duane Burton, Michael Camilleri, Alan R Zinsmeister, Adil E Bharucha

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurogastroenterology and motility, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Postprandial symptoms in patients with symptoms of gastroparesis: roles of gastric emptying and accommodation.American journal of physiology. Gastrointestinal and liver physiology · 2022
    Article
  5. Article
  6. Duodenal Mucosal Barrier in Functional Dyspepsia.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Subhankar ChakrabortyDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Anshuman DesaiDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Magnus HallandDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-4767-0146
Duane BurtonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Michael CamilleriDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-6472-7514
Alan R ZinsmeisterDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Adil E BharuchaDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-7644-0390
Mayo Clinic · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Physiological Characterization and Data Integration CoreP01DK068055 · NIDDK · MAYO CLINIC ROCHESTER · PI BHARUCHA, ADIL E., FARRUGIA, GIANRICO · 2004 to 2019
$23.8M
NCATS NIH HHS UL1 TR000135NIDDK NIH HHS P01 DK068055
6 · The paper itself

Abstract

backgroundNon-ulcer dyspepsia (NUD) is a heterogeneous disorder, which is characterized by upper gastrointestinal symptoms and sensorimotor disturbances, including abnormal gastric emptying (GE) and increased intestinal chemosensitivity, and associated with greater plasma glucagon-like peptide-1 (GLP-1) levels during duodenal lipid infusion. However, the relationship(s) between these disturbances and daily symptoms in NUD is variable. We hypothesize that abnormal GE and symptoms during a GE study and during duodenal lipid infusion are associated with the severity of daily symptoms and that GLP-1 mediates symptoms during duodenal lipid infusion in NUD.

methodsGastric emptying of solids, symptoms during the GE study and duodenal lipid infusion, and daily gastrointestinal symptoms (2 week diary) were measured in 24 healthy controls and 40 NUD patients. During duodenal lipid infusion, participants received the GLP-1 antagonist exendin 9-39 or placebo. KEY

resultsIn controls and patients, GE of solids was normal in 75% and 75%, delayed in 8% and 12.5%, or rapid in 17% and 12.5%, respectively. No controls but 26 patients (65%) had severe symptoms during the GE study. During lipid infusion, gastrointestinal symptoms were greater (P = .001) in patients and not affected by exendin. Symptoms during GE study and lipid infusion accounted for respectively 62% and 37% of variance in daily symptom severity.

conclusionsIn NUD, symptoms during a GE study and to a lesser extent during lipid infusion explain the variance in daily symptoms. Intestinal chemosensitivity is not reduced by GLP-1 antagonist. Assessment of symptoms during a GE study may provide a useful biomarker for NUD in research and clinical practice.

Indexed as

Diagnostic Techniques, Digestive SystemDuodenumAbdominal PainAdultAnxietyCase-Control StudiesDepressionDouble-Blind MethodDyspepsiaFemaleGastric EmptyingGastrointestinal TransitHeartburnHumansIntubation, GastrointestinalLipidsexendin (9-39)LipidsPeptide FragmentsgastroparesisPAGIpathophysiologyQOL

Identifiers

PMID31328363
PMCPMC6746577
OpenAlexW2963239189

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.